Global Life Science Leader [ ]
BGI’s unparalleled understanding of its clients’ competitive landscape in conjunction with best-in-class executive through board level recruiting makes it the search firm of choice with clients that are truly focused on driving their success and bringing exceptional shareholder value.
 CEO Board Executive Learn More Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value. Biotechnology Pharmaceutical Medical Device Contract Services Learn More Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value. Saving Lives Improving Treatments Learn More Maximizing Shareholder Value Finding Cures Helping Clients

Encompassing all Executive through Board Positions in Life Sciences

Director of the Board

Yes

Chief Executive Officer

Yes

Chief Business Officer

Leading publicly traded biopharmaceutical stem cell company.

No

Chairman of the Board

Yes

Chief Financial Officer

Formerly Aastrom Biosciences

Yes

Chief Operating Officer

Yes

Chief Scientific Officer

Leading publicly traded monoclonal antibody & oncology company

No

Executive Vice President, Orthopedics and Chief Operating Officer

Formerly BioMimetic Therapeutics, Inc.

Yes
See More

In The News

As BridgeBio ramps up for the launch of three new medicines and continues to channel resources into its soon-to-be-blockbuster in ATTR-CM, Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech.

https://www.fiercepharma.com/pharma/bridgebio-attracts-1b-equity-financing-launches-attruby-potential-new-products

Consumer health giant Haleon has tapped Microsoft to incorporate AI across its operations, joining a growing wave of healthcare and life sciences heavyweights turning to Big Tech to execute enterprise-wide digital overhauls.

https://www.fiercepharma.com/pharma/haleon-teams-microsoft-5-year-corporate-ai-deal-upgrade-consumer-health-operations

On a quest to bolster its life-sci contracting bona fides, self-described “multifaceted manufacturer” Kimball Electronics is going down the path of M&A.

https://www.fiercepharma.com/pharma/kimball-lays-out-103m-bolster-life-sci-cdmo-footprint-across-europe-india

Plus Therapeutics is evolving its business and has rebranded as Cerenome to reflect its expansion.

https://www.fiercepharma.com/marketing/plus-therapeutics-rebrands-cerenome-it-deepens-ai-strategy

Orca Bio has jumped into the commercial market with an FDA approval for Tregzi, a first-of-its-kind allogeneic regulatory T cell-based therapy for blood cancer patients requiring transplants.  

https://www.fiercepharma.com/pharma/fda-approves-orca-bio-cell-therapy-tregzi-blood-cancer-transplants

AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induce providers to write prescriptions for products paid for by Texas Medicaid.

https://www.fiercepharma.com/pharma/astrazeneca-will-pay-34m-settle-free-nurses-kickback-lawsuit

Piper Sandler Spring Biopharma Symposium
Boston, MA April 15-16

Needham & Co. Annual Healthcare Conference
New York, NY April 13-16

Society of Gynecologic Oncology Annual Meeting (SGO)
San Juan, Puerto Rico April 11-13

American Academy of Dermatology (AAD)
Denver, CO March 27-30

Society of Toxicology Annual Meeting (SOT)
San Diego, CA March 22-26

American Society of Clinical Oncology Genitourinary Cancers Symposium
San Francisco, CA February 26-28

See More Events

Read More Articles